Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Samuel Klein will present at the 82^nd American Diabetes Association Scientific Sessions from June 3-7, 2022, in New Orleans, LA. He will discuss the results of a Phase 1 clinical trial for pemvidutide, a dual receptor agonist targeting obesity and NASH. The presentation is scheduled for June 6, 2022, at 4:30 pm CDT, highlighting pemvidutide's potential for significant weight loss without dose adjustments. Altimmune is committed to developing innovative peptide-based therapies for metabolic and liver diseases.

Positive

• Dr. Samuel Klein's presentation on pemvidutide at the ADA Scientific Sessions could generate interest and support for the drug's development.
• Pemvidutide shows potential for rapid and significant weight loss, which may enhance market competitiveness.

Negative

• None.

GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82^nd American Diabetes Association (ADA) Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022. Dr. Klein will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.

Details for the oral presentation are as follows:

Title:	Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity
Presenter:	Sam Klein, M.D., William H. Danforth Professor of Medicine and Nutritional Science, Washington University School of Medicine
Date/Time:	Monday, June 6, 2022 at 4:30 pm CDT

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
reisenstadt@altimmune.com

FAQ

What is the purpose of the pemvidutide clinical trial presented by Altimmune?

The trial aims to assess the efficacy of pemvidutide, a dual receptor agonist, in treating obesity and NASH.

When will Dr. Samuel Klein present the results of the pemvidutide trial?

Dr. Klein will present on June 6, 2022, at 4:30 pm CDT during the ADA Scientific Sessions.

What are the expected outcomes of the pemvidutide Phase 1 trial?

The trial results indicate that pemvidutide may induce rapid and marked weight loss without the need for dose titration.

How does pemvidutide compare to other obesity treatments?

Pemvidutide is a GLP-1/glucagon dual receptor agonist, which may offer more effective weight loss compared to traditional treatments.